Dictamnine promotes apoptosis and inhibits epithelial-mesenchymal transition, migration, invasion and proliferation by downregulating the HIF-1α and Slug signaling pathways
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Dictamnine (DTM) is a natural alkaloid isolated from the root of Dictamnus dasycarpus Turcz and has been shown to exhibit multiple biological functions, including anti-inflammatory, antifungal, anti-angiogenic and anticancer activity. However, the mechanisms by which dictamnine inhibits tumor growth are not fully understood. In this study, we investigated the effectiveness of dictamnine as a treatment for cancer and to identify the underlying mechanisms of its anticancer activity. Here, dictamnine showed the potent inhibitory activity against HIF-1α and Slug activation induced by hypoxia in various human cancer cell lines. This compound markedly decreased the hypoxia-induced accumulation of HIF-1α and Slug protein in a dose-dependent manner. Further analysis revealed that dictamnine inhibited HIF-1α protein synthesis, without affecting its degradation. Our results demonstrated that dictamnine reduced HIF-1α protein synthesis by downregulating the mTOR/p70S6K/eIF4E and MAPK pathways, and reduced the expression of Slug by inhibiting the GSK-3β/Slug signaling pathway. Moreover, epithelial-mesenchymal transition (EMT) was inhibited in dictamnine-treated tumors by downregulation of HIF-1α and Slug, as reflected by the upregulation of E-cadherin and Occludin, and the downregulation of N-cadherin and Vimentin. Phenomenological experiments showed that dictamnine reduced migration and invasion, inhibited HCT116 cell proliferation and promoted HCT116 cell apoptosis by downregulating HIF-1α and Slug. In vivo studies further confirmed that dictamnine treatment caused significant inhibition of tumor growth in a xenograft tumor model. These findings suggest that dictamnine is a potent cancer inhibitor, providing a rationale for anticancer pathway-targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Redistribution of Intracellular Oxygen in Hypoxia by Nitric Oxide: Effect on HIF1α
Hagen, T., Taylor, C. T., Lam, F., & Moncada, S. (2003) · Science · doi:10.1126/science.1088805 · Cited by 704
Umezu, T., Tadokoro, H., Azuma, K., Yoshizawa, S., Ohyashiki, K., & Ohyashiki, J. H. (2014) · Blood · doi:10.1182/blood-2014-05-576116 · Cited by 600
Jin, X., Jin, H. R., Jung, H. S., Lee, S. J., Lee, J.-H., & Lee, J. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.129551 · Cited by 94
Self-citationDaxx inhibits hypoxia-induced lung cancer cell metastasis by suppressing the HIF-1α/HDAC1/Slug axis
Lin, C.-W., Wang, L.-K., Wang, S.-P., Chang, Y.-L., Wu, Y.-Y., Chen, H.-Y., Hsiao, T.-H., Lai, W.-Y., Lu, H.-H., Chang, Y.-H., et al. (2016) · Nature Communications · doi:10.1038/ncomms13867 · Cited by 86
Self-citation
Cited by
Hypoxia signaling in human health and diseases: implications and prospects for therapeutics
Luo, Z., Tian, M., Yang, G., Tan, Q., Chen, Y., Li, G., Zhang, Q., Li, Y., Wan, P., & Wu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01080-1 · Cited by 499
The crosstalk between HIFs and mitochondrial dysfunctions in cancer development
Bao, X., Zhang, J., Huang, G., Yan, J., Xu, C., Dou, Z., Sun, C., & Zhang, H. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03505-1 · Cited by 152
Shang, F.-F., Wang, J. Y., Xu, Q., Deng, H., Guo, H.-Y., Jin, X., Li, X., Shen, Q.-K., & Quan, Z.-S. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113474 · Cited by 30
Self-citation
Metadata
- Authors
- Wang, J. Y., Wang, Z., Li, M. Y., Zhang, Z., Mi, C., Zuo, H. X., Xing, Y., Wu, Y.-L., Lian, L.-H., Xu, G. H., Piao, L. X., Ma, J., & Jin, X.
- Venue
- Chemico-Biological Interactions
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 296
- Pages
- 134-144
- ISSN
- 0009-2797 (ISSN-L)
- OpenAlex
- W2892586175
- Cited by
- 50
- References
- 4
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.